



November 12, 2021

BSE Limited Code: 532321

1st Floor, P J Towers, Dalal Street, Mumbai-400001

National Stock Exchange of India Limited Code: Cadilahc

Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai-400051

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated November 12, 2021 titled "Zydus Cadila receives tentative approval from USFDA for Eluxadoline Tablets".

The contents of the press release give full details.


Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully, For, **CADILA HEALTHCARE LIMITED**

DHAVAL N. SONI COMPANY SECRETARY

Encl.: As above



Zydus Cadila receives tentative approval from USFDA for Eluxadoline Tablets

Ahmedabad, India, 12 November, 2021

Zydus Cadila's U.S. subsidiary Zydus Pharmaceuticals (USA) Inc. has received tentative approval from the USFDA to market Eluxadoline Tablets in the strengths of 75 mg and 100 mg (US RLD: VIBERZI® Tablets). Zydus' Eluxadoline Tablets are indicated in adults for the treatment of irritable bowel syndrome with diarrhea, or IBS-D. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 324 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 23000 people worldwide and is dedicated to creating healthier communities globally.

CIN: L24230GJ1995PLC025878